

Article

Therapeutic Potential of Extracts from *Macaranga tanarius* (MTE) in Diabetic Nephropathy

Yung-Chien Hsu^{1,2}, Cheng-Chih Chang³, Ching-Chuan Hsieh³ , Ya-Hsueh Shih^{1,2}, Hsiu-Ching Chang^{1,2} and Chun-Liang Lin^{1,2,4,5,6,*} 

¹ Department of Nephrology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

² Kidney and Diabetic Complications Research Team (KDCRT), Chang Gung Memorial Hospital, Chiayi 613, Taiwan

³ Division of General Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

⁴ School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan

⁵ Kidney Research Center, Chang Gung Memorial Hospital, Taipei 105, Taiwan

⁶ Center for Shockwave Medicine and Tissue Engineering, Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

* Correspondence: lynchunliang@cgmh.org.tw

Abstract: Diabetic nephropathy is a complication of diabetes that leads to end-stage kidney disease and is a major health burden worldwide. Prenylflavonoid compounds extracted from *Macaranga tanarius* (MTE) exhibit anti-inflammation, anti-oxidant, and anti-bacterial properties. However, the effects of these compounds on diabetic nephropathy remain unclear. The effects of MTE on diabetic nephropathy were investigated in vitro by using mouse renal mesangial cells and in vivo by using a db/db knockout mouse model. No overt alteration in proliferation was observed in mouse renal mesangial cells treated with 0–1 µg/mL MTE. Western blot analysis indicated that MTE dose-dependently attenuated the expression of fibronectin, α -smooth muscle actin, and collagen IV. Administration of MTE ameliorated renal albumin loss in db/db mice. Immunohistochemical staining revealed that MTE mitigated diabetes-induced fibronectin and collagen IV expression. Periodic acid–Schiff (PAS) and trichrome staining also showed that administration of MTE reduced the renal fibrosis phenomenon. MTE significantly ameliorated diabetes-induced nephropathy.

Keywords: diabetes nephropathy; fibrosis; *Macaranga tanarius* extract (MTE)



check for updates

Citation: Hsu, Y.-C.; Chang, C.-C.; Hsieh, C.-C.; Shih, Y.-H.; Chang, H.-C.; Lin, C.-L. Therapeutic Potential of Extracts from *Macaranga tanarius* (MTE) in Diabetic Nephropathy. *Plants* **2023**, *12*, 656. <https://doi.org/10.3390/plants12030656>

Academic Editor: Stefania Lamponi

Received: 28 December 2022

Revised: 20 January 2023

Accepted: 24 January 2023

Published: 2 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Diabetes mellitus (DM), one of the major metabolic disorders, has a high prevalence (approximately 10.5% of adults in 2021) worldwide [1]. The incidence of DM has increased every year and it is a significant health burden [1]. Hyperglycemia accumulates reactive oxygen species and promotes complications of DM such as cardiovascular diseases, retinopathy, and nephropathy. Diabetic nephropathy (DN) could lead to end-stage kidney disease and then cause renal dysfunction [2]. Renal fibrosis caused by the massive accumulation of extracellular matrix (ECM) including fibronectin and collagen IV in the glomerulus is the major characteristic of DN [3]. A limited number of drugs have been shown to block the progression of DN. Developing agents to rescue or attenuate the progression of DN with fewer side effects and costs is an urgent issue.

Natural compounds derived from herbs have received much interest because of their anti-oxidant, anti-inflammation, and anti-lipidemia properties. These compounds can ameliorate renal fibrosis induced by DN [4,5]. In one study, administration of Zingiber officinale extracts prevented streptozotocin (STZ)-induced renal cell apoptosis through its anti-oxidant and anti-inflammation abilities [6]. Cinnamon and its procyanidin-B2 (MTEB2)-enriched fraction attenuated urine albumin and creatinine levels in diabetic mice. In db/db mice, administration of curcumin significantly blocked the NLR family pyrin

domain containing three inflammasome signaling (NLRP3) and reduce DN progression [7]. Polyphenols from *Physalis peruviana* fruits significantly reduced serum creatinine levels and attenuated positive periodic acid–Schiff (PAS) staining signals in STZ-induced diabetic mice [8]. Chtourou et al. demonstrated that STZ induced neutrophil infiltration and hypertrophied podocyte, whereas administration of a mixture of naringin, chlorogenic acid, and quercetin significantly reversed the phenomenon [9]. Administration of Shengkang pills, a traditional Chinese medicinal formula, evidently downregulated the activities of aurora kinase B and Ras homolog family member A (RhoA) and ameliorated renal podocyte dysfunction [10]. Xu et al. demonstrated that extracts from *Ranunculus ternatus* Thunb (RTT) significantly suppressed fibronectin, α -smooth muscle actin (α -SMA) and vimentin in STZ-induced diabetic mice. The expression of inflammation factors such as NF- κ B and tumor necrosis factor- α was also mitigated by RTT [11].

Macaranga tanarius (L.) Mull.-Arg. (Euphorbiaceae) is a pioneer tree that grows first ahead of other plants on impoverished soil [12]. It grows throughout eastern and southern Asia. The root and bark of *Macaranga tanarius* are used as a folk medicine in Taiwan for treating hemoptysis and dysentery, respectively [12]. *M. tanarius* contains various chemical components such as prenylflavonoids [12], lignan glucosides [13], and terpenes [12] and exhibits a broad spectrum of biological activities. Chen et al. demonstrated that an extract from *Macaranga* exerted strong free radical scavenging activity [14]. Prenylflavonoids extracted from *Macaranga tanarius* promoted the differentiation of dental pulp stem cells via mitogen-activated protein kinase and protein kinase B pathways [15]. Treatment of L6 myotube cells with prenylflavonoids isolated from *M. tanarius* fruits dose-dependently stimulated AMP-dependent protein kinase activity and glucose transporter 1 (GLUT1) expression and triggered glucose uptake [16]. Lee et al. showed that extracts from *Macaranga tanarius* exhibited anti-bacterial and anti-fungal properties [17]. Nymphaeol-C, one chemical isolated from *Macaranga tanarius*, significantly repressed fibroblast growth factor 8 expression and its downstream signals through downregulation of β -catenin [18]. Recently, the anti-diabetes properties of prenylflavonoid have received great attention. Two prenylflavonoids from *Epimedii Herba* prevented advanced glycation end-product formation and may exhibit an anti-diabetes ability [19]. Zhao et al. demonstrated that prenylflavonoid glycosides extracted from *Epimedium koreanum* attenuated lung fibrosis formation [20]. Xanthohumol, a prenylated flavonoid, enhanced the activity of nuclear factor erythroid 2-related factor 2 (Nrf2) and subsequently facilitated wound healing in diabetic mice [21]. Administration of 10 mg/kg O-prenylated flavonoid purified from *Melicope lunu-ankenda* leaves for 20 days evidently attenuated blood glucose levels in streptozotocin (STZ)-induced diabetic mice [22]. No study has reported the effects of prenylflavonoid compounds (MTE) derived from *Macaranga tanarius* on diabetic complications. In the present study, we investigated the effects of MTE on DN.

2. Results

2.1. Cytotoxicity Effect of MTE on Mouse Renal Mesangial Cells

To evaluate the cytotoxicity of MTE on mouse renal mesangial cells, we treated the cells with different concentrations of MTE for 12, 24, 48, or 72 h. Figure 1 shows no overt alteration in the mouse renal mesangial cells in the presence of high glucose combined with 0, 0.01, 0.05, 0.1, 0.5, and 1 μ g/mL MTE for the indicated times.

To determine whether MTE influences the expression of fibrosis-related proteins, we conducted Western blot analysis. The expression of fibronectin, α -smooth muscle actin, and collagen IV increased nearly five-fold in response to high glucose treatment. A low dose of MTE (below 0.5 ng/mL) did not affect high glucose-induced fibrosis-related protein expression whereas a high dose of MTE (1 and 1.5 μ g/mL) reversed the high glucose-induced phenomenon (Figure 2).




Figure 1. Cytotoxicity of prenylflavanone compounds of mouse renal mesangial cells. The mouse renal mesangial cells were treated with the indicated concentrations of MTE for 12, 24, 48, and 72 h (from upper to lower). The cell morphology was pictured by light contract microscope.




Figure 2. MTE mitigated the expression of fibrosis-related proteins in diabetic mice. The mouse renal mesangial cells were treated with 0, 0.01, 0.05, 0.1, 0.5, and 1 and µg/mL MTE in the presence of high glucose for 48 h. Cells in the absence of high glucose were used as a negative control (Con). Proteins were extracted and subjected to Western blot analysis (upper panel). b-actin was used as a loading control. Lower panel: the data represent the means and standard error obtained from at least three independent experiments. *: $p < 0.05$ compared to the control group. #: $p < 0.05$ compared to the db/db group.

2.2. Effects of MTE on Renal Fibrosis In Vivo

To further investigate the effects of MTE on diabetes-induced renal fibrosis, we developed animal models. The body weights and HbA1C levels of the db/db knockout mice with or without MTE were significantly higher than those of the db/m control mice. Interestingly, the albumin loss significantly increased to 0.368 in the db/db mice compared

with that (0.010) in the db/m mice. Administration of 50 or 100 mg/kg MTE attenuated the albumin loss to 0.144 and 0.198, respectively. The same is also true for the kidney weight. No overt alterations were found in kidney weight/body weight and total protein loss (Table 1).

Table 1. Effect of PPG on HbA1C, body weight, kidney weight, albumin loss, and total protein loss in diabetic rats.

	db/m	db/db		
	(n = 6)	0 MTE (n = 6)	50 mg/kg MTE (n = 6)	100 mg/kg MTE (n = 6)
HbA1C	4.12 ± 0.16	10.38 ± 0.79 *	9 ± 3.64 *	9.12 ± 0.89 *
Kidney weight	0.30 ± 0.03	0.42 ± 0.03 *	0.36 ± 0.15 *,#	0.38 ± 0.03 *,#
Body weight	32.56 ± 1.70	49.34 ± 4.66 *	50.65 ± 7.02 *	48.44 ± 4.42 *
Kidney weight/body weight	0.93 ± 0.10	0.86 ± 0.09	0.72 ± 0.30	0.80 ± 0.11
Albumin loss	0.0097 ± 0.0033	0.3685 ± 0.2393 *	0.1436 ± 0.2514 *,#	0.1981 ± 0.1227 *,#

*: $p < 0.05$ compared to the db/m group. #: $p < 0.05$ compared to the db/db without MTE treatment group.

To validate whether MTE affects the expression of fibrosis-related genes, we performed quantitative RT-PCR analysis. As shown in Figure 3, the mRNA levels of fibronectin significantly increased by nearly four-folds in the db/db mice, whereas administration of MTE (50 or 100 mg/kg) reduced gene expression. Similarly, administration of MTE also repressed the expression of TGF- β and collagen IV in the db/db mice.




Figure 3. MTE reversed the diabetes-induced expression of fibrosis-related genes. (A) Renal tissue sections before (upper panel) and after (lower panel) laser capture microdissection. Quantitative RT-PCR analysis of (B) fibronectin, (C) TGF- β , and (D) collagen IV from the indicated treatment. The data represent the means and standard error obtained from at least three independent experiments *: $p < 0.05$ compared with db/m mice. #: $p < 0.05$ compared with db/db mice without MTE.

Immunohistochemical staining for collagen IV and fibronectin was conducted to verify the effect of MTE on the expression of fibrosis-related proteins. As shown in Figure 4,

the expression of fibronectin and collagen IV was significantly enhanced in the db/db mice. Administration of 50 and 100 mg/kg MTE obviously mitigated the increase in the expression of fibronectin and collagen IV in the db/db mice.




Figure 4. MTE altered the expression of fibrosis-related proteins in diabetic mice. Immunohistochemical staining using anti-fibronectin (A) and collagen IV (B) antibodies of glomerulus derived from the dd/db mice administered with 0, 50, or 100 mg/kg MTE. db/m mice were used as a negative control. The lower panel represents the means and standard deviation of IDO obtained from six mice. *: $p < 0.005$ compared with db/m mice. #: $p < 0.005$ compared with db/db mice without MTE. Scale bar: 100 μm at 100 \times and 20 μm at 1000 \times .

To further determine whether MTE reverses renal fibrosis in db/db mice, we performed trichrome and PAS staining. Increased trichrome staining intensity was found in db/db mice, whereas administration of MTE reversed the phenomenon (Figure 5A). Elevated PAS staining intensity was observed in db/db mice, whereas MTE dose-dependently decreased the PAS signal (Figure 5B).




Figure 5. MTE reduced renal fibrosis in the diabetic mice. Trichrome (A) and PAS (B) staining of glomerulus derived from dd/db mice given 0, 50, or 100 mg/kg MTE. The db/m group was used as a negative control. (B) The lower panel represents the means and standard deviation of IDO obtained from six mice. *: $p < 0.005$ compared with the db/m mice. #: $p < 0.005$ compared with the db/db mice without MTE. Scale bar: 100 μm at 100 \times and 20 μm at 1000 \times .

3. Discussion

Diabetes is a major metabolic disease and its prevalence is set to increase annually from 10% in 2021 to an estimated 12.2% in 2045 [23]. DN, one of the complications of diabetes, is the major risk factor for causing end-stage kidney disease [24]. In the pro-

gression of DN, hyperglycemia promotes the generation of reactive oxygen species (ROS), triggers inflammation, accumulates ECM, and eventually induces renal fibrosis and renal dysfunction [25]. Flavonoids extracted from plants have received great attention because of their anti-diabetes properties [5]. In this study, we demonstrated the effects of MTE from *M. tanarius* on diabetic nephropathy.

Hyperglycemia triggers damage to podocytes, leading to albumin excretion and DN progression [26]. In the present study, the administration of MTE significantly reduced albumin loss in diabetic mice. In line with our observations, several reports have indicated that flavonoids ameliorate diabetes-induced renal albumin loss. Treatment with tangeretin reduced hyperglycemia-induced renal podocyte injury and recovered renal albumin excretion in db/db mice [27]. In STZ-induced diabetic mice, the levels of serum creatinine and urine increased, whereas administration of *Andrographis paniculata* extract reversed the STZ-induced phenomenon [28]. Li et al. showed that grape seed proanthocyanidin extracts (GSPE) significantly reduced urine albumin excretion and serum creatinine levels in STZ-induced diabetic mice [29]. Administration of a water extract of *Hydrangea paniculata* significantly improved the renal function of diabetic mice as evidenced by increased creatine clearance and decreased urine albumin loss [30]. Widyarini et al. demonstrated that *Etlingera elatior* ethanol extract reduced blood glucose levels and protected renal function by decreasing urine albumin secretion in STZ-induced diabetic mice [31]. Overall, our results indicate that MTE reversal of albumin loss in diabetic mice may ameliorate podocyte injury and block DN progression.

The main pathological characteristic of DN is renal fibrosis caused by renal interstitial inflammation, fibroblast proliferation, and excessive extracellular matrix (ECM) deposition [25]. Fibronectin, α -smooth muscle actin (α -SMA), and collagen IV, which are the three major compounds of ECM, participate in renal fibrosis progression [32,33]. Plant extracts suppress the expression of fibrosis-related proteins and ameliorated DN. Yang et al. demonstrated that a Fufang Zhenzhu Tiaozhi capsule (FTZ), which is composed of eight Chinese traditional herbs, dose-dependently inhibited diabetic-induced fibronectin and collagen IV expression [34]. A Huangkui capsule combined with metformin repressed high glucose-induced tumor growth factor β -1 (TGF- β 1) and fibronectin expression in in vitro and in vivo experiments [17]. Xu et al. showed that RTT mitigated renal fibrosis-related protein expression through downregulation of SMYD2 (30%), H3K36me3, and H3K4me3 (53% and 75%, respectively) expression [11]. An extract of *Polygala fallax* Hemsl (EPF) reduced IL-1 β , TNF- α , fibronectin, and collagen IV expression in high glucose-treated human glomerular mesangial cells which suggests that the compounds attenuated DN progression [35]. Moreover, EPF also mitigated the expression of matrix metalloproteinase -2 and -9 [35]. In db/db diabetic mice, administration of 10 and 50 mg/kg *Polygoni avicularis*-ethanol soluble fraction (ER-PA) significantly reduced inflammation cytokines, TGF, and collagen IV expression [36]. In this study, MTE dose-dependently reduced fibronectin, α -SMA, and collagen IV in renal mesangial cells in the presence of high glucose. Quantitative RT-PCR and immunohistochemical staining analysis also revealed that MTE obviously attenuated fibrosis-related protein expression in db/db diabetic mice. Moreover, PAS and trichrome staining indicated that MTE repressed renal fibrosis in db/db diabetic mice. Collectedly, our results show that MTE exhibited anti-renal fibrosis in diabetic mice.

4. Materials and Methods

4.1. Sample Preparation

The study materials were provided by NatureWise Biotech & Medicals Corporation (Taipei, Taiwan). Powdered dry leaves of *M. tanarius* (1.5 kg) were immersed in acetone (4.5 L) at room temperature. After filtering, the filtrate was concentrated under reduced pressure to obtain the acetone extract. The extract was resuspended in acetone, mixed with active charcoal powder, filtered by celite 545 on a Büchner funnel, and eluted with aqueous MeOH solution. The 90% MeOH layer was collected and separated by Sephadex LH-20 gel eluted with MeOH to obtain the prenylflavonoid-enriched fraction, which was purified by

low-pressure Daiso SP-120-ODS-BP gel (40–60 μm) column to obtain the prenylflavonoids-enriched component. The major compounds of the prenylflavonoid-enriched fraction contained Propolin C (PPC), Propolin D (PPD), and Propolin G (PPG). The recovery rate of prenylflavonoid-enriched component from 1.5 kg dry *M. tanarius* leaves was about 2.63%. The component was finally dissolved in 50% propylene glycol aqueous solution for activity studies. We used a 1:1000 dilution to treat the cells, so the final concentration of propylene glycol was 0.5% in the culture medium.

4.2. Cell Culture

The mouse renal mesangial cells were purchased from the American Type Culture Collection (ATCC) and maintained in Dulbecco's modified Eagle's medium (DMEM)/F12 medium containing 5% fetal bovine serum. In the control group, the cells were treated with 5.5 mM D-glucose. In the high-glucose group, the cells were stimulated with 25 mM D-glucose for 24 or 48 h. All of the cells were cultured at 37 °C with 5% carbon dioxide.

4.3. Quantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR)

Total RNAs of glomerular mesangium obtained through a VERITAS™ laser-captured dissection system were extracted by TRI Reagent. In brief, 1 μg of total RNA was subjected to first cDNA synthesis and a quantitative polymerase chain reaction [37]. The PCR conditions and primer sequences have also been described in a previous report [37].

4.4. Western Blot Analysis

The cells were treated with 0, 0.01, 0.05, 0.1, 0.5, and 1 mg/mL MTE in the presence of 25 mM glucose for 48 h. Proteins were extracted by RIPA buffer. About 30 μg of proteins were separated by 10% sodium dodecyl sulfate–polyacrylamide gel and transferred into a nitrocellulose membrane. The membranes were blocked by phosphate buffer saline (PBS) containing 5% non-fat milk and incubated in the indicated antibody at 4 °C overnight. The membranes were incubated with an anti-mouse or anti-rabbit second antibody conjugated with horseradish peroxidase for 1 h at room temperature. Signals were detected by an enhanced chemiluminescent kit.

4.5. Animal Model

Eighteen 6-week-old db/db mice (C57BLKS/J Iar-+Leprdb/+Leprdb) were obtained from Jackson Laboratory and randomly divided into three groups: (1) 0 MTE; (2) 50 mg/kg MTE; and (3) 100 mg/kg MTE for 8 weeks (five times per week). Six age-matched db/m mice were used as the negative control group. At the end of the experiment, their body weight, hemoglobin A1C (HbA1C), urine albumin, and urine total protein were measured as described in a previous report [38]. The mice were sacrificed, and their kidneys were immediately removed and weighed. All of the protocols of the animal experiments were certified by the Institutional Animal Care and Use Committee of the Chang Gung Memorial Hospital.

4.6. Histological Staining and Immunohistochemical Analysis

The 4 μm paraffin-embedded renal tissue sections were subjected to deparaffinization and rehydration. Three percent H₂O₂ was used to remove endogenous peroxidase activity. The antigen was retrieved by boiling in 10 mM of citrate buffer (pH 6.0) for 20 min. The sections were incubated with the indicated antibody, and positive signals were detected using a horseradish peroxidase-3-3-diaminobenzidine kit (BioGenex, San Ramon, CA, USA). Hematoxylin staining was conducted as counterstaining.

Masson's trichrome and periodic acid–Schiff (PAS) staining were performed to analyze collagen deposition and mesangial matrix expansion [15,17]. The quantitative integrated optical density (IOD) was measured as described in a previous report [15].

4.7. Statistical Analysis

All data were presented by means \pm standard error obtained from at least three experiments. Significance was measured by the Student's *t*-test using SPSS version 15. A *p*-value < 0.05 was considered significantly different.

5. Conclusions

In the presented study, we demonstrated that MTE mitigated high glucose-induced fibronectin, α -SMA, and collagen IV expression in cultured renal mesangial cells. Similarly, our results showed that MTE attenuated the expression of fibrosis-related proteins in a db/db diabetic mouse model. In addition, MTE significantly suppressed the excretion of renal albumin. These findings suggested that MTE negatively regulated DN and may be a potential agent for ameliorating DN progression.

Author Contributions: Conceptualization, Y.-C.H.; methodology, C.-C.C.; software, C.-C.H.; validation, C.-C.C. and C.-C.H.; data curation, Y.-H.S. and H.-C.C.; writing—original draft preparation, C.-L.L.; writing—review and editing, C.-L.L.; funding acquisition, C.-L.L. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by CORPG6G0011-3 and CMRPG6K0221-3 from Chang Gung Memorial Hospital.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank the Research Center of NatureWise Biotech & Medical Corporation for providing and analyzing the compounds from *Macaranga tanarius*.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Ogurtsova, K.; Guariguata, L.; Barengo, N.C.; Ruiz, P.L.; Sacre, J.W.; Karuranga, S.; Sun, H.; Boyko, E.J.; Magliano, D.J. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. *Diabetes Res. Clin. Pract.* **2022**, *183*, 109118. [[CrossRef](#)] [[PubMed](#)]
- Whiting, D.R.; Guariguata, L.; Weil, C.; Shaw, J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res. Clin. Pract.* **2011**, *94*, 311–321. [[CrossRef](#)]
- Bhattacharjee, N.; Barma, S.; Konwar, N.; Dewanjee, S.; Manna, P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. *Eur. J. Pharmacol.* **2016**, *791*, 8–24. [[CrossRef](#)] [[PubMed](#)]
- Ahmed, Q.U.; Ali, A.H.M.; Mukhtar, S.; Alsharif, M.A.; Parveen, H.; Sabere, A.S.M.; Nawi, M.S.M.; Khatib, A.; Siddiqui, M.J.; Umar, A.; et al. Medicinal Potential of Isoflavonoids: Polyphenols That May Cure Diabetes. *Molecules* **2020**, *25*, 5491. [[CrossRef](#)]
- Vargas, F.; Romecin, P.; Garcia-Guillen, A.I.; Wangesteen, R.; Vargas-Tendero, P.; Paredes, M.D.; Atucha, N.M.; Garcia-Estan, J. Flavonoids in Kidney Health and Disease. *Front. Physiol.* **2018**, *9*, 394. [[CrossRef](#)]
- Al Hroob, A.M.; Abukhalil, M.H.; Alghonmeen, R.D.; Mahmoud, A.M. Ginger alleviates hyperglycemia-induced oxidative stress, inflammation and apoptosis and protects rats against diabetic nephropathy. *Biomed. Pharmacother.* **2018**, *106*, 381–389. [[CrossRef](#)]
- Suresh Babu, P.; Srinivasan, K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. *Mol. Cell Biochem.* **1998**, *181*, 87–96. [[CrossRef](#)]
- Ezzat, S.M.; Abdallah, H.M.I.; Yassen, N.N.; Radwan, R.A.; Mostafa, E.S.; Salama, M.M.; Salem, M.A. Phenolics from *Physalis peruviana* fruits ameliorate streptozotocin-induced diabetes and diabetic nephropathy in rats via induction of autophagy and apoptosis regression. *Biomed. Pharmacother.* **2021**, *142*, 11948. [[CrossRef](#)] [[PubMed](#)]
- Chtourou, Y.; Morjen, M.; Ammar, R.; Mhiri, R.; Jemaa, M.; ELBini-Dhouib, I.; Fetoui, H.; Srairi-Abid, N.; Marrakchi, N.; Jebali, J. Investigation of the Renal Protective Effect of Combined Dietary Polyphenols in Streptozotocin-Induced Diabetic Aged Rats. *Nutrients* **2022**, *14*, 2867. [[CrossRef](#)] [[PubMed](#)]
- Wang, F.; Fan, J.; Pei, T.; He, Z.; Zhang, J.; Ju, L.; Han, Z.; Wang, M.; Xiao, W. Effects of Shenkang Pills on Early-Stage Diabetic Nephropathy in db/db Mice via Inhibiting AURKB/RacGAP1/RhoA Signaling Pathway. *Front. Pharmacol.* **2022**, *13*, 781806. [[CrossRef](#)] [[PubMed](#)]
- Xu, W.; Peng, R.; Chen, S.; Wu, C.; Wang, X.; Yu, T.; Jian, J.; Zhang, N.; Zuo, S.; Chen, M.; et al. *Ranunculus ternatus* Thunb extract attenuates renal fibrosis of diabetic nephropathy via inhibiting SMYD2. *Pharm. Biol.* **2022**, *60*, 300–307. [[CrossRef](#)]

12. Kawakami, S.; Harinantenaina, L.; Matsunami, K.; Otsuka, H.; Shinzato, T.; Takeda, Y. Macaflavanones A-G, prenylated flavanones from the leaves of *Macaranga tanarius*. *J. Nat. Prod.* **2008**, *71*, 1872–1876. [[CrossRef](#)] [[PubMed](#)]
13. Matsunami, K.; Otsuka, H.; Kondo, K.; Shinzato, T.; Kawahata, M.; Yamaguchi, K.; Takeda, Y. Absolute configuration of (+)-pinoresinol 4-O-[6"-O-galloyl]-beta-D-glucopyranoside, macarangiosides E, and F isolated from the leaves of *Macaranga tanarius*. *Phytochemistry* **2009**, *70*, 1277–1285. [[CrossRef](#)]
14. Chien, Y.H.; Yu, Y.H.; Ye, S.R.; Chen, Y.W. Antibacterial and Antioxidant Activity of the Fruit of *Macaranga tanarius*, the Plant Origin of Taiwanese Green Propolis. *Antioxidants* **2022**, *11*, 1242. [[CrossRef](#)]
15. Nam, S.H.; Yamano, A.; Kim, J.A.; Lim, J.; Baek, S.H.; Kim, J.E.; Kwon, T.G.; Saito, Y.; Teruya, T.; Choi, S.Y.; et al. Prenylflavonoids isolated from *Macaranga tanarius* stimulate odontoblast differentiation of human dental pulp stem cells and tooth root formation via the mitogen-activated protein kinase and protein kinase B pathways. *Int. Endod. J.* **2021**, *54*, 1142–1154. [[CrossRef](#)]
16. Natsume, N.; Yonezawa, T.; Saito, Y.; Woo, J.T.; Teruya, T. Prenylflavonoids from fruit of *Macaranga tanarius* promote glucose uptake via AMPK activation in L6 myotubes. *J. Nat. Med.* **2021**, *75*, 813–823. [[CrossRef](#)]
17. Lee, J.H.; Kim, Y.G.; Khadke, S.K.; Yamano, A.; Woo, J.T.; Lee, J. Antimicrobial and antibiofilm activities of prenylated flavanones from *Macaranga tanarius*. *Phytomedicine* **2019**, *63*, 153033. [[CrossRef](#)]
18. Yoshimura, K.; Hosoya, T.; Fujinami, M.; Ohta, T.; Kumazawa, S. Nymphaeol-C, a prenylflavonoid from *Macaranga tanarius*, suppresses the expression of fibroblast growth factor 18. *Phytomedicine* **2017**, *36*, 238–242. [[CrossRef](#)] [[PubMed](#)]
19. Nakashima, K.; Miyashita, H.; Yoshimitsu, H.; Fujiwara, Y.; Nagai, R.; Ikeda, T. Two new prenylflavonoids from *Epimedium Herba* and their inhibitory effects on advanced glycation end-products. *J. Nat. Med.* **2016**, *70*, 290–295. [[CrossRef](#)] [[PubMed](#)]
20. Zhao, Y.D.; Zhang, X.; Yang, W.Y.; Zhang, R.Q.; Mu, L.T.; Han, L.; Lv, C.N.; Lu, J.C. New anti-pulmonary fibrosis prenylflavonoid glycosides from *Epimedium koreanum*. *Chin. J. Nat. Med.* **2022**, *20*, 221–228. [[CrossRef](#)] [[PubMed](#)]
21. Lu, X.; Liu, M.; Dong, H.; Miao, J.; Stagos, D.; Liu, M. Dietary prenylated flavonoid xanthohumol alleviates oxidative damage and accelerates diabetic wound healing via Nrf2 activation. *Food. Chem. Toxicol.* **2022**, *160*, 112813. [[CrossRef](#)] [[PubMed](#)]
22. George, S.; Ajikumar Nair, S.; Johnson, A.J.; Venkataraman, R.; Baby, S. O-prenylated flavonoid, an antidiabetes constituent in *Melicope lunu-ankenda*. *J. Ethnopharmacol.* **2015**, *168*, 158–163. [[CrossRef](#)]
23. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res. Clin. Pract.* **2019**, *157*, 107843. [[CrossRef](#)] [[PubMed](#)]
24. Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res. Clin. Pract.* **2022**, *183*, 109119. [[CrossRef](#)]
25. Humphreys, B.D. Mechanisms of Renal Fibrosis. *Annu. Rev. Physiol.* **2018**, *80*, 309–326. [[CrossRef](#)]
26. Lee, E.Y.; Kim, G.T.; Hyun, M.; Kim, S.; Seok, S.; Choi, R.; Lee, M.Y.; Chung, C.H. Peroxisome proliferator-activated receptor-delta activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. *Nephrol. Dial. Transplant.* **2012**, *27*, 4069–4079. [[CrossRef](#)]
27. Kang, M.K.; Kim, S.I.; Oh, S.Y.; Na, W.; Kang, Y.H. Tangeretin Ameliorates Glucose-Induced Podocyte Injury through Blocking Epithelial to Mesenchymal Transition Caused by Oxidative Stress and Hypoxia. *Int. J. Mol. Sci.* **2020**, *21*, 8577. [[CrossRef](#)] [[PubMed](#)]
28. Hidayat, R.; Wulandari, P. Effects of *Andrographis paniculata* (Burm. F.) Extract on Diabetic Nephropathy in Rats. *Rep. Biochem. Mol. Biol.* **2021**, *10*, 445–454. [[CrossRef](#)]
29. Li, X.; Gao, Z.; Gao, H.; Li, B.; Peng, T.; Jiang, B.; Yang, X.; Hu, Z. Nephrin loss is reduced by grape seed proanthocyanidins in the experimental diabetic nephropathy rat model. *Mol. Med. Rep.* **2017**, *16*, 9393–9400. [[CrossRef](#)]
30. Sen, Z.; Weida, W.; Jie, M.; Li, S.; Dongming, Z.; Xiaoguang, C. Coumarin glycosides from *Hydrangea paniculata* slow down the progression of diabetic nephropathy by targeting Nrf2 anti-oxidation and smad2/3-mediated profibrosis. *Phytomedicine* **2019**, *57*, 385–395. [[CrossRef](#)]
31. Widyarini, T.; Indarto, D.; Soetrisno, S.; Purwanto, B. Modulation effects of *Etlingera elatior* ethanol extract as anti-inflammatory on chronic kidney disease in mice with hypertension and diabetes. *J. Popul. Ther. Clin. Pharmacol.* **2022**, *29*, e140–e149. [[PubMed](#)]
32. Choi, D.; Kim, C.L.; Kim, J.E.; Mo, J.S.; Jeong, H.S. Hesperetin inhibit EMT in TGF-beta treated podocyte by regulation of mTOR pathway. *Biochem. Biophys. Res. Commun.* **2020**, *528*, 154–159. [[CrossRef](#)] [[PubMed](#)]
33. Tang, R.; Xiao, X.; Lu, Y.; Li, H.; Zhou, Q.; Kwadwo Nuro-Gyina, P.; Li, X. Interleukin-22 attenuates renal tubular cells inflammation and fibrosis induced by TGF-beta1 through Notch1 signaling pathway. *Ren. Fail.* **2020**, *42*, 381–390. [[CrossRef](#)] [[PubMed](#)]
34. Yang, Y.Q.; Tan, H.B.; Zhang, X.Y.; Zhang, Y.Z.; Lin, Q.Y.; Huang, M.Y.; Lin, Z.Y.; Mo, J.Z.; Zhang, Y.; Lan, T.; et al. The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease. *J. Ethnopharmacol.* **2022**, *292*, 115165. [[CrossRef](#)] [[PubMed](#)]
35. Wang, M.; Liu, X.; Wang, Z.; Xu, Q. The extract of *Polygala fallax* Hemsl. slows the progression of diabetic nephropathy by targeting TLR4 anti-inflammation and MMP-2/9-mediated anti-fibrosis in vitro. *Phytomedicine* **2022**, *104*, 154251. [[CrossRef](#)]
36. Yoon, J.J.; Park, J.H.; Lee, Y.J.; Kim, H.Y.; Han, B.H.; Jin, H.G.; Kang, D.G.; Lee, H.S. Protective Effects of Ethanolic Extract from Rhizome of *Polygoni avicularis* against Renal Fibrosis and Inflammation in a Diabetic Nephropathy Model. *Int. J. Mol. Sci.* **2021**, *22*, 7230. [[CrossRef](#)]

37. Hsu, Y.C.; Ho, C.; Shih, Y.H.; Ni, W.C.; Li, Y.C.; Chang, H.C.; Lin, C.L. Knockout of KLF10 Ameliorated Diabetic Renal Fibrosis via Downregulation of DKK-1. *Molecules* **2022**, *27*, 2644. [[CrossRef](#)]
38. Kumarappan, C.T.; Mandal, S.C. Polyphenolic extract of *Ichnocarpus frutescens* attenuates diabetic complications in streptozotocin-treated diabetic rats. *Ren. Fail.* **2008**, *30*, 307–322. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.